Follicular Lymphoma
News
Polatuzumab outperforms pinatuzumab in non-Hodgkin lymphoma
Polatuzumab vedotin plus rituximab produced more durable responses than did pinatuzumab vedotin plus rituximab in patients with relapsed or...
News
High survival in relapsed FL after primary radiotherapy
The study supports the role of primary radiotherapy in the treatment of early-stage follicular lymphoma. But researchers found that patients who...
News
Anthracyclines, bendamustine are options for grade 3A follicular lymphoma
A CVP chemotherapy regimen performed poorly compared with anthracycline-based chemotherapy in advanced stage follicular lymphoma.
News
Daratumumab disappoints in non-Hodgkin lymphoma trial
The drug, used in multiple myeloma, was safe but ineffective in patients with non-Hodgkin lymphoma.
News
BCL expression intensity key in distinguishing FL lesions
BCL2 expression intensity is the “single most valuable clue” in differentiating primary cutaneous follicular center-cell lymphoma from secondary...
News
Study supports need for less toxic therapies in FL
The study examines causes of death for follicular lymphoma patients in the rituximab era.
Article
Emerging biosimilars market presents opportunities and challenges
Conference Coverage
Phase 3 study confirms biosimilarity of PF-05280586 with rituximab
PF-05280586 showed biosimilarity to rituximab at up to 26 weeks in a randomized phase 3 study of treatment-naive patients with CD20-positive LTB-...
News
FDA approves biosimilar rituximab for NHL
The U.S.
News
FDA approves rituximab biosimilar for lymphoma
Truxima is the first biosimilar approved in the United States to treat non-Hodgkin lymphoma.